Literature DB >> 7933209

Nonsurgical management of threatened upper urinary tracts and incontinence in children with myelomeningocele.

R D Hernandez1, R S Hurwitz, J E Foote, P E Zimmern, G E Leach.   

Abstract

The 2 major urological objectives in treating the child with myelomeningocele are to preserve renal function and achieve continence. We report our success in managing these cases with nonsurgical therapy. From 1981 to 1991, 45 patients with myelomeningocele 1 to 15 years old were evaluated urodynamically before and after initiating nonsurgical treatment. Pretreatment urodynamics identified 2 groups. Group 1 consisted of 31 patients with leak point pressure of 40 cm. water or more of whom 10 had grades II to V/V vesicoureteral reflux and 4 had moderate or severe hydronephrosis. Group 2 consisted of 14 incontinent patients with leak point pressure of less than 40 cm. water and no reflux or hydronephrosis. Both groups were treated with intermittent catheterization, anticholinergic medications and fluid restriction. Within a mean followup of 5.5 years nonsurgical intervention resulted in lowering maximum detrusor pressure at maximum cystometric capacity to less than 40 cm. water in 22 of 31 group 1 patients (71%), and in resolving vesicoureteral reflux in 7 of 10 (70%) and hydronephrosis in 3 of 4 (75%) group 1 patients. Of 4 patients in group 1 with persistent high grade vesicoureteral reflux or severe hydronephrosis 3 (10%) required augmentation cystoplasty. With nonsurgical management 18 patients (40%) were completely continent, 18 (40%) required 2 or less pads daily and 9 (20%) required more than 2 pads daily. Nonsurgical management alone was effective in preserving the upper urinary tract in 90% of patients and it provided satisfactory continence in 80%. Surgical management should be reserved for the minority of patients whose upper tract changes do not resolve and for those whose degree of continence is not satisfactory with nonsurgical management.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7933209     DOI: 10.1016/s0022-5347(17)32480-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

Review 1.  Neurogenic bladder.

Authors:  S K Agarwal; D J Bagli
Journal:  Indian J Pediatr       Date:  1997 May-Jun       Impact factor: 1.967

2.  Repeated injections of intradetrusor onabotulinumtoxinA as adjunctive treatment of children with neurogenic bladder.

Authors:  Cristian Sager; Carol Burek; Juan Bortagaray; Juan Pablo Corbetta; Santiago Weller; Victor Durán; Juan Carlos Lopez
Journal:  Pediatr Surg Int       Date:  2014-01       Impact factor: 1.827

3.  Augmentation ureterocystoplasty with ipsilateral renal preservation in the management of patients with compromised renal function secondary to dysfunctional voiding.

Authors:  R F Talic
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 4.  Botulinum toxin for the management of bladder dysfunction.

Authors:  Brigitte Schurch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  [Botulinum toxin in urology. An inventory].

Authors:  H Schulte-Baukloh; H H Knispel
Journal:  Urologe A       Date:  2004-08       Impact factor: 0.639

6.  Pediatric enterocystoplasty: long-term complications and controversies.

Authors:  Eric A Kurzrock
Journal:  World J Urol       Date:  2008-10-10       Impact factor: 4.226

Review 7.  A case for botulinum toxin-A in idiopathic bladder overactivity.

Authors:  Christopher P Smith; George T Somogyi; Michael B Chancellor; Rodney A Appell
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

8.  Pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a.

Authors:  Cristian Sager; Carol Burek; Victor Durán; Juan Pablo Corbetta; Santiago Weller; Bortagaray Juan; Juan Carlos López
Journal:  ISRN Urol       Date:  2012-06-07

9.  Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children.

Authors:  Mazen Zeino; Tanja Becker; Mark Koen; Christoph Berger; Marcus Riccabona
Journal:  Cent European J Urol       Date:  2012-09-04

10.  Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment.

Authors:  Tufan Tarcan; Cem Akbal; Cağri A Sekerci; Tuncay Top; Ferruh Simşek
Journal:  Korean J Urol       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.